Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Biosimilar Trends Report

- PMLiVE

Amgen promotes Esteban Santos

He succeeds Madhavan Balachandran as executive vice president of operations

- PMLiVE

SMC rejects Amgen’s Repatha over lack of outcomes data

But gives GlaxoSmithKline’s asthma drug Nucala the green light

- PMLiVE

SMC approves Amgen orphan drug for use in NHS Scotland

Also accepts AbbVie's former orphan drug Duodopa, but rejects Sanofi's Jevtana

Biosimilars – the Brexit of the pharmaceutical industry?

In this article, Senior Consultant Jenna Earl explains what factors influence the uptake of biosimilars in the UK, comparing them to the same principles that help us navigate the complexities...

Blue Latitude Health

- PMLiVE

Biosimilar trastuzumab comparable to brand, ASCO hears

Roche’s Herceptin matched in safety and efficacy by Mylan and Biocon’s breast cancer drug

Free Thinking: Are biosimilars the answer to the rising cost of RA treatment?

In a past Free Thinking paper, we looked at the opportunity and challenges for biosimilar mAbs entering the rheumatoid arthritis market. A few years later and according to our Therapy...

Research Partnership

EU flag

Second Remicade biosimilar given green light in Europe

Samsung Bioepis’ Flixabi provides another lower-cost treatment option

Video: Global Biosimilars Market

Research director of Therapy Watch, Laurent Chanroux, discusses the growth opportunities for biosimilars and the importance of adaptable market tracking for pre and post product launch

Research Partnership

National Institute for Health and Care Excellence NICE logo

NICE persuaded to back Praluent as well as Repatha

Comes after Sanofi follows Amgen in discounting the price of its drug

- PMLiVE

Does safety sell medicines?

Is pharmacovigilance unnecessary policing or a strategic asset for pharma companies?

- PMLiVE

Remicade safe from biosimilar competition this year, says J&J

Will defend the blockbuster’s US patents should Celltrion's Inflectra launch in 2016

- PMLiVE

New biosimilars group will tackle slow uptake in UK

Has pledged to increase access to lower-priced versions of biologic drugs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links